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Abstract The ability of the 72 kDa gelatinase A to cleave the 
amyloid protein precursor (APP) was investigated. HeLa cells 
were transfected with an APP695 plasmid. The cells were incu- 
bated with gelatinase A, which cleaved the 110 kDa cell-surface 
APP, releasing a 100 kDa form of the protein. A peptide homol- 
ogous to the i~l-secretase site was cleaved by gelatinase A adjacent 
to a glutamate residue at position -3  (~A4 numbering system). 
A peptide homologous to the ~-secretase site was not cleaved. 
The results demonstrate that 72 kDa gelatinase A is not an 
~-secretase, but that it may have a i~l-seeretase activity. 
l~,,y words: Alzheimer's disease; Amyloid; Gelatinase; 
S~cretase; Protease 
1. Introduction 
An early event in the pathogenesis of Alzheimer's disease 
(AD) is the deposition i  the brain of amyloid fibrils assembled 
fi~gm the 4 kDa amyloid protein (flA4) [1]. flA4 is derived from 
a segment of the fl-amyloid protein precursor (APP), a mem- 
b~ane-spanning glycoprotein, flA4 is thought o result from 
woteolysis of APP by a fl-secretase [2,3] which cleaves close to 
met-596 (APP695 numbering) leading to production of poten- 
tially amyloidogenic carboxyl-terminus fragments of APP. An 
a ternative processing route involving an ~-secretase which 
cleaves APP within the amyloid sequence is not thought o 
c,,ntribute to amyloid formation [2,3]. 
Although the sites of action of the ~- and fl-secretases within 
tlte APP sequence are well documented, the proteases have not 
b,:en unequivocally identified and characterised [3,4]. The iden- 
t~ fication and characterisation f APP secretases i  important 
fi ,r development of therapeutic strategies to control the build 
u 9 of amyloid in the brain and the pathological effects of AD 
[:]. 
A report by Miyazaki et al. [6] suggested that a 72 kDa 
n ~etalloproteinase, gelatinase A, may have ~-secretase activity. 
q heir studies howed that a synthetic peptide homologous to 
r,~sidues 10-20 in flA4 was cleaved by gelatinase A at a lysine 
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residue known to be the site of cleavage of the ~-secretase. 
However, as gelatinase A was activated by a procedure mploy- 
ing trypsin digestion and stromelysin activation, it was not 
conclusively demonstrated in that study that the activated ge- 
latinase A was free of trypsin activity. Furthermore, Walsh et 
al. [7] found that a specific inhibitor of gelatinase A (TIMP-1) 
failed to inhibit he secretion of APP from PC12 cells and were 
unable to detect any 72 kDa gelatinase A in the medium condi- 
tioned by PC12 cells. 
The aim of the present study was to examine the putative 
secretase activity of gelatinase A. We studied the release of 
membrane-bound APP from HeLa cells transiently transfected 
with an APP695 cDNA. Our findings upport he view that the 
72 kDa gelatinase A is not an c~-secretase, and they suggest that 
the protease may have a fl-secretase-like activity. 
2. Materials and methods 
2.1. Materials 
Naphthol AS-MX phosphate, Fast red and 4-aminophenylmercuric 
acetate (APMA) were purchased from Sigma Chemical Co. (St. Louis, 
MO, USA). Rainbow molecular weight markers for western blotting 
were purchased from Amersham Australia Pty. Ltd~ (Castle Hill, NSW, 
Australia). Dulbecco's MEM was obtained from Life Technologies Pty. 
Ltd. (Mt. Waverley, Victoria, Australia). Keratanase (EC 3.2.1.103) 
was from Seikagaku (Kogyo, Japan). The primary antibody used in 
western immunoblotting, which recognizes an epitope near the amino- 
terminus of APP, was a mouse monoclonal ntibody (22C11) raised 
against a recombinant APP695 bacterial fusion protein [8]. Affinity 
purified anti-rabbit mmunoglobulin G conjugated to alkaline phos- 
phatase was from Promega (Sydney, NSW, Australia). Synthetic C- 
terminally amidated peptides were synthesised bythe Fmoc procedure 
[9]. The first peptide, designated Pb, was homologous tothe fl-secretase 
cleavage site in APP695 between residues 588 and 601 (TEE- 
ISEVKMDAEFR-NHz). The second peptide, designated Pm was ho- 
mologous to the a-secretase cl avage site in APP695 between residues 
606 and 619 (flA4~0_23, YEVHHQKLVFFAED-NH2). The aggrecan 
G l-G2 fragments were prepared as previously described by Fosang and 
Hardingham [10], Recombinant human progelatinase A (MMP-2, EC 
3.4.24.24) was purified to apparent homogeneity asassessed by SDS 
polyacrylamide g lelectrophoresis [11]. The purified proenzyme, when 
activated possessed a molecular mass of 72 kDa and possessed a specific 
activity towards 14C-labelled gelatin of 464 units/nmol [11]. Just prior 
to its use, the proenzyme was activated by incubation for 2 h at 25°C 
or 22 h at 37°C with 2 mM 4-aminophenylmercuric acetate (APMA). 
2.2. HeLa cell culture and transfection 
HeLa cells were transiently transfected bycalcium phosphate copre- 
cipitation with a plasmid (pAD-695) encoding the 695-amino acid form 
of APP [8,12]. The following day, cells were subcultured into 6-well 
plastic ulture dishes at a density of 2 x 105 cells/well in Dulbecco's 
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modified Eagles medium containing 10% fetal calf serum. After 24 h, 
the medium was removed and the cells in each well were washed with 
2 × 1 ml of serum-free medium. 
2.3. APP release experiments 
HeLa cells were incubated with 200/A/well of serum-free medium 
containing 0.1% (w/v) Na-azide for 15 min at 37 °C to inhibit en- 
dogenous release of APP [12]. Activated 72 kDa gelatinase A was added 
at various concentrations i  a total volume of 50/11 of buffer (20 mM 
Tris-HC1, pH 7.5 containing 10 mM CaCI2) and the cells were incubated 
for 30 min at 37 °C. The buffer was then removed and concentrated 
to 40 ml by filtration through Centricon-30 concentrators (Amicon, 
Beverly, MA) and then analysed by Western blotting as previously 
described [12]. 
2.4. Digestion of synthetic peptides 
Aliquots of activated 72 kDa gelatinase A (1 ,ug) were incubated for 
18 h at 37 °C with 25/lg of peptide in a total volume of 50/.tl of 20 mM 
Tris-HCl, pH 7.5 containing 10 mM CaCI2. The digestion was stopped 
by adding 0.1 volumes of glacial acetic acid. The mixture was centri- 
fuged in a Beckman microfuge at 10,000 × g for 15 min at 4 °C and then 
the digests were analysed by reversed phase high performance liquid 
chromotography on a Waters C18 Novapak column (0.4 × 150 mm) 
using an Applied Biosystems 400 solvent delivery system. The absorb- 
ance at 214 nm was monitored using an Applied Biosystems 1000S 
detector. Peptides were eluted with a linear gradient of 0-60% (v/v) 
acetonitrile in 0.1% (v/v) trifluoroacetic acid/H20 at a flow rate of 
1 ml/min over 60 min [12]. Peptides eluting from the column were 
identified by amino acid sequencing using an Applied Biosystems model 
470A sequencer with an on-line 120A PTH-amino acid analyser, as well 
as commercially by Chiron Mimotopes Pty. Ltd. (Clayton, Australia) 
by time-of-flight mass spectrometry using an API Sciex II LC/MS/MS 
system (Perkin Elmer Sciex, Thornhill, Canada). 
2.5. Digestion of aggrecan- G1-G2 fragment 
Gelatinase A digestion of aggrecan-G l-G2 fragment was carried out 
in 50 mM Tris-HC1 buffer pH 7.5 containing 10 mM CaC12 and 100 mM 
NaCI for 18 h at 37 °C. The digestions were stopped by the addition 
of 10 mM ethylenediaminetetraacetic id and 2 mM 1,10-phenanthro- 
line. The digestion of the G l-G2 fragment of aggrecan was analysed by 
5% polyacrylamide g l electrophoresis in the presence of sodium do- 
decyl sulfate as described by Fairbanks et al. [13]. Gels were stained 
with silver to visualise the products of digestion [14]. 
3. Results 
Initially, we examined the possibility that gelatinase A could 
release APP from the surface of intact cells. HeLa cells were 
transiently transfected with an APP695 cDNA and the cells 
incubated with various concentrations of gelatinase A. All incu- 
bations were performed in triplicate. Similar results were ob- 
tained in each incubation. In the absence of gelatinase A, no 
APP release into the medium was detected (Fig. 1, lane 2). At 
the lowest concentration of gelatinase A employed (10 ng/ml), 
no released immunoreactive APP was detected (lane 3). How- 
ever, at 100 ng/ml gelatinase A, a 100-110 kDa band was seen 
(lane 4). This band was approximately 10 kDa lower in molec- 
ular mass than the major cellular form of APP [8,15,16]. At the 
highest concentration f gelatinase A (1 pg/ml), a second cleav- 
age product of 70 kDa was detected (lane 5). There was no 
difference in the APP immunoreactivity in the cells following 
gelatinase A treatment (data not shown). 
These findings indicated that gelatinase A could release APP 
from the cell surface with a secretase-like action, although they 
did not indicate the position of the cleavage site in APE To 
address this question, synthetic peptides homologous to the 
~-and fl-secretase cleavage sites were incubated with gelatinase 
A, and the products of digestion were analysed by reversed 
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Fig. 1. Release of APP immunoreactivity by 72 kDa gelatinase A from 
transiently APP695-transfected HeLa cells. HeLa cells were transfected 
with an APP695 cDNA (pAD-695), treated with Na-azide to inhibit 
endogenous secretion of APP, and then incubated for 30 rain at 37°C 
with gelatinase A. The APP-immunoreactivity in the HeLa cells (lane 
1) and the immunoreactivity released into the medium (lanes 2-5) were 
analysed by western blotting using a monoclonal antibody (22C11) 
which recognises APP. The total oading of concentrated medium was 
M/A/lane in lanes 2 5. The amount of cell protein applied in lane 1 was 
equivalent to 1.1 × 105 cells. The positions of Rainbow molecular 
weight markers (Amersham Australia Pty. Ltd., North Ryde, Austra- 
lia) are shown. 
phase high performance liquid chromatography. When peptide 
P~ (YEVHHQKLVFFAED-NH2) homologous to the ~-secre- 
tase site on APP was incubated with a high concentration of
gelatinase A (ratio ofpeptide to gelatinase A = 25/lg:l/ .tg) for 
22 h at 37 °C, no breakdown of the peptide was detected (Fig. 
2C,D). 
A synthetic peptide P, (TEEISEVKMDAEFR-NH2) homol- 
ogous to the region of APP cleaved by fl-secretasc was cleaved 
by gelatinase A to yield two major peptide fragments (Fig. 2B). 
Amino acid sequencing demonstrated that the two products 
(peaks 1 and 2) eluting at 17.1 min and 20.8 min respectively, 
were the N and C-terminal fragments of Pfl, respectively, fol- 
lowing cleavage of the peptide bond between residues 6 and 7. 
Peak 3 was identified as the undigested peptide by both N- 
terminal amino acid sequencing and by time-of-flight mass 
spectrometry. 
To confirm that the gelatinase A was fully active, the same 
preparation of activated gelatinase A was incubated with the 
G1-G2 fragment of the proteoglycan aggrecan. Previous stud- 
ies [17 ]have shown that this fragment of aggrecan is an excel- 
lent substrate for gelatinase A. The G1-G2 digests were analy- 
sed by polyacrylamide gel electrophoresis in the presence of 
0.1% sodium dodecyl sulfate according to Fairbanks et al. [13]. 
Analysis of the digestion pattern of the GI -G2 fragment on 
silver-stained gels confirmed that gelatinase A cleaved the GI -  
G2 fragment (Fig. 3, lanes 2,3). Progelatinase A showed a low 
but significant ability to degrade aggrecan-G1-G2 (Fig. 3, lanes 
4,5). 
4. Discussion 
In this study, the ability of the 72 kDa gelatinase A to cleave 
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Fi:g. 2. Elution profile from reversed phase high performance liquid chromatography of peptides after digestions with 72 kDa gelatinase A. Peptide 
P[~ (A,B) and peptide P~ (C,D) (25/2g) were incubated for 18 h at 37 °C in the absence (A,C) or presence (B,D) of 1/2g of 72 kDa gelatinase in a 
to1 al volume of 50/21. The digests were analysed by reversed phase HPLC on a Waters Novopak C 18 column (0.4 × 150 mm). The column was eluted 
w~th a linear gradient of 0-60% acetonitrile over 60 min in 0.1% (v/v) trifluoroacetic acid:water at a flow rate of 1 ml/min. Peptides were detected 
b~ measuring the absorbance at214 nm. The peptides l and 2 were identified by amino acid sequencing and peptide 3 by amino acid sequencing 
al~d by time-of-flight mass spectrometry. 
APP was investigated. APP was released from the surface of 
APP695-transfected HeLa cells, indicating that gelatinase A
d,,es have some ability to cleave APP specifically at a site near 
the membrane. Despite this result, gelatinase A did not exhibit 
my c~-secretase activity as shown by the fact that it did not 
cl~:ave a peptide homologous to the ~-secretase cleavage site. 
However, gelatinase A showed much greater specificity for 
cl,:aving a synthetic peptide homologous to the region cleaved 
b3 fl-secretase. Furthermore, the site of cleavage by gelatinase 
A (position -3,  using the flA4 numbering system) is a known 
cl,:avage site by a fl-secretase [3]. 
We were unable to reproduce the finding of Miyazaki et al. 
[6i that gelatinase A cleaves like an c~-secretase. The reason for 
this result is unclear. However, one major difference between 
our studies and those of Miyazaki et al. is that we did not use 
tr epsin and stromelysin to activate gelatinase A. In experiments 
aere we attempted to reproduce the activation conditions 
el aployed by Miyazaki et al. [6], we were unable to convincingly 
el minate the possibility of trypsin contamination i the final 
p~eparation. This difficulty is of some importance, as the ~- 
sccretase site is adjacent o a lysine residue which can also be 
cl,zaved by trypsin. Because we were unable to eliminate the 
trepsin activity, we employed APMA activation instead. Al- 
though it could be argued that gelatinase A shows a completely 
different pattern of protease cleavage specificity depending 
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Fig. 3. Analysis of the digestion of purified aggrecan G l-G2 fragment 
(5 mg/ml) by progelatinase or 72 kDa gelatinase by SDS-poly- 
acrylamide gel electrophoresis. Each lane was loaded with the equiva- 
lent of 0.5/2g of the original undigested G1-G2 fragment. All samples 
were pretreated with 0.025 units/30/21 of keratanase (Pseudomonas sp. 
from Seikagaku, Japan) for 6 h before electrophoresis. Polypeptides 
were visualised by staining with silver. Lane 1, G1-G2 fragment; lanes 
2 and 4, G1-G2 fragment digested with 5/2g/ml enzyme; lanes 3 and 5, 
G1-G2 fragment digested with 10/2g/ml enzyme. In lanes 2 and 3 digests 
were with 72 kDa gelatinase, and in lanes 4 and 5, digests were per- 
formed with progelatinase. Progelatinase was activated with 2 mM 
APMA for 22 h at 37 °C. 
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upon the method of activation, there is no evidence for this 
from our studies. 
Our results raise the possibility that gelatinase A could have 
fl-secretase activity. However, more evidence is needed to estab- 
lish this view. Although the main cleavage site for fl-secretase 
is on the N-terminal side of Asp 1, other minor sites have been 
identified [3]. For example, in human kidney 293 cells, APP can 
also be cleaved between Glu -4 and Va1-3 [18,19]. Studies using 
COS cells [20] and MDCK cells [21] have also identified a 
similar cleavage site. 
As both APP and gelatinase A are processsed through a 
secretory pathway, it is possible that they may be co-localised 
in a subcellular compartment. Alternatively, some release of 
APP may occur from the cell surface following digestion with 
an extracellular p otease such as gelatinase A. The concept hat 
gelatinase A may be a fl-secretase is further supported by the 
observation that it is produced and secreted from neuronal cells 
[22]. 
Our finding that gelatinase A has a fl-secretase-like activity 
adds another enzyme to the growing list of candidate//-secre- 
tases (reviewed in [3]). Only further studies will establish 
whether any of these enzymes acts as a fl-secretase in vivo. In 
view of the fact that several cleavage sites have been identified 
close to the N-terminal portion of the flA4 sequence [18-21], 
it is quite possible that more than one protease may act in this 
capacity. 
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